- Home
- VNRX vs BOLD Comparison
VNRX vs BOLD Comparison
Compare VNRX & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNRX
- BOLD
- Stock Information
- Founded
- VNRX N/A
- BOLD 2018
- Country
- VNRX United States
- BOLD United States
- Employees
- VNRX N/A
- BOLD N/A
- Industry
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BOLD
- Sector
- VNRX Health Care
- BOLD
- Exchange
- VNRX Nasdaq
- BOLD Nasdaq
- Market Cap
- VNRX 52.4M
- BOLD 24.4M
- IPO Year
- VNRX N/A
- BOLD 2024
- Fundamental
- Price
- VNRX $0.66
- BOLD $1.12
- Analyst Decision
- VNRX Strong Buy
- BOLD Buy
- Analyst Count
- VNRX 5
- BOLD 3
- Target Price
- VNRX $3.88
- BOLD $4.00
- AVG Volume (30 Days)
- VNRX 280.5K
- BOLD 279.9K
- Earning Date
- VNRX 08-13-2025
- BOLD 08-11-2025
- Dividend Yield
- VNRX N/A
- BOLD N/A
- EPS Growth
- VNRX N/A
- BOLD N/A
- EPS
- VNRX N/A
- BOLD N/A
- Revenue
- VNRX $1,308,361.00
- BOLD N/A
- Revenue This Year
- VNRX $563.72
- BOLD N/A
- Revenue Next Year
- VNRX $160.43
- BOLD N/A
- P/E Ratio
- VNRX N/A
- BOLD N/A
- Revenue Growth
- VNRX 64.16
- BOLD N/A
- 52 Week Low
- VNRX $0.40
- BOLD $1.00
- 52 Week High
- VNRX $0.94
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- VNRX 47.72
- BOLD N/A
- Support Level
- VNRX $0.62
- BOLD N/A
- Resistance Level
- VNRX $0.71
- BOLD N/A
- Average True Range (ATR)
- VNRX 0.08
- BOLD 0.00
- MACD
- VNRX -0.02
- BOLD 0.00
- Stochastic Oscillator
- VNRX 12.93
- BOLD 0.00
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.